ДВЕНАДЦАТИМЕСЯЧНЫЕ РЕЗУЛЬТАТЫ ЧКВ С ИСПОЛЬЗОВАНИЕМ СИРОЛИМУС И ЭВЕРОЛИМУС ПОКРЫТЫХ СТЕНТОВ

1. Р. С. Поляков, Ю. М. Саакян, А. Г. Билич, М. В. Пурецкий, В. М. Сысоев, С. А. Абугов. Пятилетние результаты коронарной ангиопластики с использованием стентов с лекарственным покрытием: клиническая эффективность и безопасность. Кардиология и сердечно-сосудистая хирургия. 2008; 4: 15–20.

2. Antoinette de Waha, Salvatore Cassese, Robert Byrne, Tomohisa Tada, lamin king, Adnan Kastrati, and Albert Schoemig. Everolimus-eluting versus sirolimus-eluting stents a meta-analysis of randomized trials J. Am. Coll. Cardiol. 2012; 59; E1507.

3. Biondi-Zoccai G. G., Lotrionte M., Agostoni P., Abbate A., Fusaro M., Burzotta F., Testa L., Sheiban I., Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006; 27: 2667–2674.

4. Byrne R. A. Two-year outcomes after everolimusor sirolimus-eluting stents in patients with coronary artery disease in the ISAR TEST 4 Trial. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.

5. Caixeta A., Leon M. B., Lansky A. J., Nikolsky E., Aoki J., Moses J. W., Schofer J., Morice M. C., Schampaert E., Kirtane A. J., Popma J. J., Parise H., Fahy M., Mehran R. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J. Am. Coll. Cardiol. 2009 Sep. 1; 54 (10): 894–902.

6. Cutlip D. et al. ARC definitions of stent thrombosis. Circulation. 2007; 115: 2344–2351.

7. Fajadet J., Morice M. C., Bode C., Barragan P., Serruys P. W., Wijns W., Constantini C. R., Guermonprez J. L., Eltchaninoff H., Blanchard D., Bartorelli A., Laarman G. J., Perin M., Sousa J. E., Schuler G., Molnar F., Guagliumi G., Colombo A., Ban Hayashi E., Wülfert E. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005 Mar 1; 111 (8): 1040–4.

8. J. Eduardo Sousa, MD, PhD; J. Ribamar Costa, Jr, MD; Alexandre Abizaid, MD, PhD10-Year Follow-Up of the First Cypher Stent Implanted in Human An Invasive Evaluation With Angiography, Intravascular Ultrasound, and Optical Coherence Tomography J.Am. Coll. Cardiol Intv. 2010; 3 (5): 556–558.

9. Jensen L. O., Thayssen P., Hansen H. S., Christiansen E. H., Tilsted H. H., Krusell L. R., Villadsen A. B., Junker A., Hansen K. N., Kaltoft A., Maeng M, Pedersen K. E., Kristensen S. D. et. al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).

10. Joner M., Finn A. V., Farb A., Mont E. K., Kolodgie F. D., Ladich E., Kutys R., Skorija K., Gold H. K., Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193–202.

11. Joner M., Nakazawa G., Finn A. V. et al. Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents. J Am Coll Cardiol 2008; 52 (5): 333–42.

12. Juan A. Herrador MD*, Juan C. Fernandez MD, Manuel Guzman MD, Victor Aragon MD. Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions Catheterization and Cardiovascular Interventions Volume 78, Issue 7, pages 1086–1092, 1 December 2011.

13. Kandzari D. E., Leon M. B., Popma J. J. et al. Comparison of zotarolimuseluting and sirolimuseluting stents in patients with native coronary artery disease. J Am Coll Cardiol 2006; 48: 2440–7.

14. Kastrati A., Dibra A., Eberle S. et al. Sirolimuseluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294 (7): 819–25.

15. Kedhi E., Joesoef K. S., McFadden E. et al. Secondgeneration everolimus-eluting and paclitaxeleluting stents in real-life practice.Lancet 2010; 375: 201–9.

16. Kereiakes D. J., Choo J. K., Young J. J., Broderick T. M. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004; 5: 9–15.

17. Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman and Harvey D. White: theWriting Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. European Heart Journal (2012) 33, 2551–2567.

18. Lorenz Räber, Michael Magro, Giulio G. Stefanini, Bindu Kalesan, Ron T. van Domburg, Yoshinobu Onuma, Peter Wenaweser, Joost Daemen, Bernhard Meier, Peter Jüni, Patrick W. Serruys, Stephan Windecker. Very Late Coronary Stent Thrombosis of a Newer Generation Everolimus-Eluting Stent Compared with Early Generation Drug-Eluting Stents: A Prospective Cohort Study. CIRCULATION AHA, 1, 2012.

19. Lorenz Räber, Peter Jüni, Eveline Nüesch, Bindu Kalesan, Peter Wenaweser, Aris Moschovitis, Ahmed A. Khattab, Maryam Bahlo, Mario Togni, Stéphane Cook, Rolf Vogel, Christian Seiler, Bernhard Meier, Stephan Windecker. Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization. Journal of the American College of Cardiology Vol. 57, № 21, 2011, 2143–2151.

20. McFadden E. P., Stabile E., Regar E., Cheneau E., Ong A. T., Kinnaird T., Suddath W. O., Weissman N. J., Torguson R., Kent K. M., Pichard A. D., Satler L. F., Waksman R., Serruys P. W. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519–1521.

21. Mehta S. R., Bassand J. P., Chrolavicius S., Diaz R., Eikelboom J. W., Fox K. A., Granger C. B., Jolly S., Joyner C. D., Rupprecht H. J., Widimsky P., Afzal R., Pogue J., Yusuf S. CURRENT-OASIS 7 Investigators N Engl J Med. 2010 Sep 2; 363 (10): 930–42.

22. Meier P., Lansky A. J. Optimal duration of clopidogrel therapy: the shorter the longer? EurHeart J. 2012 Nov 7.

23. Morice M. C., Serruys P. W., Sousa J. E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–1780.

24. Morice M. C., Serruys P. W., Barragan P., Bode C., Van Es G. A., Stoll H. P., Snead D., Mauri L., Cutlip D. E., Sousa E. et al. Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents. Five-Year Results of the RAVEL Trial Journal of the American College of Cardiology October 2007 volume 50, issue 14 pp 1299–1304.

25. Moses J. W., Leon M. B., Popma J. J., Fitzgerald P. J., Holmes D. R., O’Shaughnessy C., Caputo R. P., Kereiakes D. J., Williams D. O., Teirstein P. S., Jaeger J. L., Kuntz R. E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315–1323.

26. Onuma Y., Kukreja N., Piazza N. et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH registry. J Am Coll Cardiol 2009; 54: 269–76.

27. Damman P., MD, Abdel-Wahab M., MD, Möllmann H., MD, Richardt G., MD, Chevalier B., MD, Barragan P., MD, Tijssen J. G. P., PhD, Underwood P., MD, Hamm C. W., MD. Comparison of Twelve-Month Outcomes After Percutanous Coronary Intervention With Everolimus- Eluting Versus Zotarolimus-Eluting or Sirolimus Eluting Stents From the PROENCY (PROmus ENdeavor CYpher) Registry J INVASIVE CARDIOL 2012; 24 (10): 495–502

28. Pilar Jiménez-Quevedo1, Manel Sabaté, Dominick J. Angiolillo, Fernando Alfonso, Rosana Hernández-Antolín, Marcelo SanMartín et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial European Heart Journal (2007) 28, 1946–1952/

29. Räber L., Windecker S. Current status of drugeluting stents. Cardiovasc Ther 2010 Mar 27 [E-pub ahead of print].

30. Rasmussen K., Maeng M., Kaltoft A. et al. Efficacy and safety of zotarolimus-eluting and sirolimuseluting coronary stents in routine clinical care Lancet 375: 1090–9.

31. Schampaert E., Cohen E. A., Schlüter M. et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110

32. Schofer J., Schlüter M., Gershlick A. H. et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (ESIRIUS). Lancet 2003; 362: 1093–9.

33. Schomig A., Dibra A., Windecker S. et al. A metaanalysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007;.50: 1373–80.

34. Sedrani R., Cottens S., Kallen J. et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998; 30 (5): 2192–4.

35. Serruys P. W., Kutryk M. J. B., Ong A. T. L. Coronaryartery stents. N Engl J Med. 2006; 354: 483–495.

36. Serruys P. W., Ruygrok P., Neuzner J. et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent. EuroIntervention 2006; 2: 286–94.

37. Sethi A., Bahekar A., Bhuriya R., Bajaj A., Singh P. P., Arora R., Khosla S. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials. Arch Cardiovasc Dis. 2012 Nov; 105 (11): 544–56.

38. Sousa J. E., Costa M. A., Abizaid A. et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. Circulation 2001; 103: 192–5.

39. Sripal Bangalore, MD, MHA; Sunil Kumar, MD; Mario Fusaro, MD; Nicholas Amoroso, MD; Michael J. Attubato, MD; Frederick Feit, MD; Deepak L. Bhatt, MD, MPH; James Slater, MD. Shortand Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents A Mixed-Treatment comparison Analysis of 117762 Patient-Years of Follow-Up From Randomized Trials. Circulation June 12, 2012.; 125: 2873–2891.

40. Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis Lancet 2007; 370: 937–48.

41. Stone G. W., Ellis S. G., Cox D. A., Hermiller J., O’Shaughnessy C., Mann J. T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J. J., Russell M. E. for the TAXUS-IV Investigators. A polymerbased, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350: 221–231.

42. Stone G. W., Midei M., Newman W. et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. JAMA 2008; 299: 1903–13.

43. Stone G. W., Rizvi A., Newman W. et al. Everolimuseluting versus paclitaxel- eluting stents in coronary artery disease. N Engl J Med 362: 1663–74.

44. Lüscher T. F., Steffel J., Eberli F. R., Joner M., Nakazawa G., Tanner F. C., Virmani R. Drug- Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications. Circulation. 2007; 115: 1051–1058.

45. Windecker S., Remondino A., Eberli F. R. et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353 (7): 653–62.